Another Alzheimer’s disease drug has failed to help patients. This time, it’s verubecestat, a BACE inhibitor from Merck .
Category: Alzheimer’s
A Potential $20 Billion Indication? 2 Must-Have Biotechs Taking on Alzheimer’s Disease
Alzheimer’s disease is a terrible illness which affects an estimated 5.4 million Americans today. Alzheimer’s is also the 6th leading cause of death nationally.
Acadia Pharmaceuticals’ Alzheimer’s Data Raises Some Questions
However, the trial results do raise some important questions regarding the durability of Nuplazid’s benefit and the likelihood of a phase 3 success. Can Nuplazid deliver an important win for Acadia in this tough-to-treat disease? In this clip from The Motley Fool’s Industry Focus: Healthcare podcast, analyst Kristine Harjes is joined by contributor Todd Campbell to discuss the trial results and highlight what should be on investors’ minds as Acadia Pharmaceuticals preps for phase 3 studies.